289 related articles for article (PubMed ID: 32512672)
1. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
2. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
Hicks C; Isaacs A; Wong R; Chong BH
Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
[TBL] [Abstract][Full Text] [Related]
4. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
[TBL] [Abstract][Full Text] [Related]
5. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
7. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
8. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Hicks C; Wong R; Manoharan A; Kwan YL
Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
[TBL] [Abstract][Full Text] [Related]
9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre.
Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M
Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941
[TBL] [Abstract][Full Text] [Related]
11. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
De Rosa L; Anghel G; Pandolfi A; Riccardi M; Amodeo R; Majolino I
Int J Hematol; 2004 Jan; 79(1):85-91. PubMed ID: 14979484
[TBL] [Abstract][Full Text] [Related]
12. Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.
Millar BC; Millar JL; Bell JB; Raje N; Milan S; Mehta J; Singhal S; Middleton GW; Sheperd V; Catovsky D; Powles RL
Bone Marrow Transplant; 1996 Nov; 18(5):871-8. PubMed ID: 8932839
[TBL] [Abstract][Full Text] [Related]
13. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
14. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Badros A; Barlogie B; Siegel E; Roberts J; Langmaid C; Zangari M; Desikan R; Shaver MJ; Fassas A; McConnell S; Muwalla F; Barri Y; Anaissie E; Munshi N; Tricot G
Br J Haematol; 2001 Sep; 114(4):822-9. PubMed ID: 11564069
[TBL] [Abstract][Full Text] [Related]
15. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
[TBL] [Abstract][Full Text] [Related]
16. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
17. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: effect of the CD34+ cell dose.
Diaz MA; Vicent MG; Garcia-Sanchez F; Vicario JL; Madero L
Vox Sang; 2000; 79(3):145-50. PubMed ID: 11111232
[TBL] [Abstract][Full Text] [Related]
18. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
Raina V; Sharma A; Kumar R; Bhargava M
Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
[TBL] [Abstract][Full Text] [Related]
19. The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma.
Kazmi MA; Ahsan G; Schey SA
Clin Lab Haematol; 2001 Apr; 23(2):125-9. PubMed ID: 11488852
[TBL] [Abstract][Full Text] [Related]
20. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.
Chhabra S; Thapa B; Szabo A; Konings S; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Johnson BD; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2011-2017. PubMed ID: 32717431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
